- Original Article
Plain radiography in patients treated with intrathecal drug delivery using an implantable pump device
Insights into Imagingvolume 8, pages499–511 (2017)
Intrathecal drug administration using an implanted pump system is well established in intractable spasticity and pain. However, despite continuous advancements in manufacturing technology, adverse events related to the pump and catheter still occur. Most of them, such as migration, damage, disconnection and occlusion, are related to the spinal catheter. The aim of this overview is to update radiologists on how plain radiography of the implanted delivery system for intrathecal drug administration should be interpreted and to increase awareness for the need of urgent and timely multidisciplinary troubleshooting.
Plain radiographic images of patients treated with intrathecal drug administration using an implantable drug delivery system were analysed in a multidisciplinary setting at our (university) referral centre for complications in intrathecal drug administration.
Examples of catheter-related adverse events are described and a proposal is made for stepwise interpretation of standard plain radiographic images.
Plain radiological images are the mainstay for the diagnosis of catheter-related adverse events in intrathecal drug delivery. Radiologists play an important role in an early diagnosis. An awareness of abnormal radiological findings seems important to avoid a life-threatening withdrawal syndrome.
• Untimely cessation of intrathecal drug delivery can lead to a life-threatening withdrawal syndrome.
• Initially mild symptoms can lead to an exacerbation of a withdrawal syndrome.
• Most intrathecal catheter-related problems are visible on plain radiography.
• Common causes of catheter problems are migration, lacerations, occlusion and disconnection.
• Knowledge on implanted intrathecal catheters is crucial for interpretation of plain radiography.
For over 30 years intrathecal drug delivery systems have been successfully applied in thousands of patients for the management of spasticity [1, 2] and dystonia (both intrathecal baclofen) , and for chronic pain (intrathecal analgesic drugs) [4, 5]. Compared with oral administration, infusion directly into the cerebrospinal fluid (CSF) has an extended treatment effect and with fewer unwanted side effects [1, 6]. There is general consensus that intrathecal therapy should be reserved for patients who have an insufficient response to more conservative therapies and/or for patients who experience serious side effects .
Despite generally favourable and safe outcomes [8, 9] and continuous advancements in manufacturing technology, pump and catheter-related adverse events still occur . Although the benefits usually outweigh the risks , even limited exposure to adverse events remains a problem. Early recognition of complications and their prompt management is needed.
Most of the drug delivery device-related adverse events are caused by intrathecal catheter failure [12,13,14]. Approximately 15–40% of patients experienced catheter complications [2, 15,16,17,18]. With the newly developed Ascenda catheter instead of the older silicone catheters, a tremendous reduction from 18 to 1.1% was reported by Motta and Antonello . The main reasons for this are migration, lacerations, occlusion and disconnection of the catheter, which cause a sudden cessation of intrathecal drug administration. Abrupt interruption of intrathecal baclofen delivery can present within several to 48 h with a spectrum of signs and symptoms. Then, the initially mild symptoms of exacerbation of spasticity, fever, excessive sweating and pruritus can escalate to a life-threatening multi-organ failure. Over time, hyperthermia develops with values up to 42° C , accompanied by nausea, respiratory distress, hypotension, tachycardia, hallucinations, delirium, disorientation, psychosis, sometimes with seizures, rhabdomyolysis with increased creatinine kinase levels resulting in disseminated intravascular coagulation and multi-organ failure [13, 21,22,23,24,25,26,27,28,29]. In rare cases, intrathecal baclofen withdrawal can even be fatal [30, 31]. The symptoms are probably related to the release of excitatory neurotransmitters that occurs when baclofen-mediated inhibition GABA-B effect is abruptly interrupted [32,33,34]. The heterogeneous symptoms occurring during withdrawal of intrathecal baclofen and of intrathecal opioid treatment may result in misdiagnosis, wrong referrals and (eventually) in a disastrous treatment delay. An additional problem is the referral of the patient in good time to a specialised centre, which is a requisite for successful treatment . Different imaging techniques, including plain radiography, fluoroscopy with contrast material injection via the access port of the pump, CT myelography, MRI and 111In-DTPA scintigraphy, are used to diagnose malfunction of the drug delivery system [14, 36,37,38,39,40,41]. Of all these imaging modalities, plain radiography is the most important, especially in an acute situation. Furthermore, a rigorous and adequate interpretation of the images by the radiologist is crucial to make a correct diagnosis and, if necessary, implement (urgent) interventions.
This overview aims to offer the radiologist a systematic approach for the evaluation of all parts of the intrathecal delivery system on plain radiography. This may help radiologists to identify causes of drug delivery failures in emergency and in chronic situations.
Materials and methods
Below, we describe the most commonly used methods: (1) intrathecal drug delivery system, (2) intrathecal catheter and (3) surgical implantation technique.
Intrathecal drug delivery system
Although several pump systems are available, the implantable Synchromed II pump (Medtronic, Minneapolis, MN, USA) is by far the most rigorously tested and most applied implanted programmable device, worldwide (Fig. 1). Here, we focus on this pump only.
The implantable Synchromed II pump and the related intrathecal catheters have received the Conformité Européenne (CE) mark and are approved by the U.S. Food and Drug Administration (FDA) for treatment of pain and spasticity. During continuous intrathecal drug delivery, the prescribed medication is administered through an intrathecal catheter, connected with an implantable programmable pump system. The pump provides precise intrathecal drug delivery to patients with spasticity or chronic intractable pain. Via the refill septum, which is in the centre of the device (Fig. 1a), the reservoir is filled percutaneously. The gas below the reservoir exerts pressure which advances the drug into the inner tubing of the pump. The accompanying programmer device enables the delivery rate and mode to be programmed. A rotor system pushes the programmed dose with precision through the catheter access port via the catheter into the intrathecal space.
Over time, several catheter types for the implantable Synchromed II pump have been developed and are commercially available. Although two types of intrathecal catheters (the 8731SC, and the Ascenda) are currently available, older types are still in use. Determining the type of implanted catheter via plain radiography is important for correct interpretation.
The 8731SC catheter is normally visible on plain radiography (Fig. 2; see Table 1 for a key to the symbols used in the figures). The pump-catheter connection is sutureless and the two segments of the catheter have a different diameter, i.e. the pump segment of the catheter has a larger outer diameter than the spinal segment. Furthermore, the 8731SC catheter is provided with a two-pin catheter-catheter connector, a folded V-wing anchor which is fixed on the fascia, and has a catheter-end with six side holes and a round titanium tip. The folded V-wing in the 8731SC catheter locks the catheter in place (Fig. 2c, d) and is, therefore, important for the diagnosis of catheter disorders. A partially or completely unfolded anchor (see Fig. 9) creates a major risk for dislodgement, potentially leading to a complete migration.
The Ascenda catheter (Fig. 3) has a poor opacity and the pump-catheter connection is also sutureless. Both catheter segments have the same diameter and are connected to each other with a needle connector. The fixation on the fascia is conducted by an unfolded V-wing anchor (Fig. 3c, d). This catheter also has a catheter-end with six side holes and a round titanium tip. In contrast to the 8731SC catheter, the unfolded V-wing in the Ascenda catheter locks the catheter in place.
Older catheters have a sutured pump-catheter connection and distinct differences in anchoring (this could even be absent), different catheter-catheter connection, different catheter ends, and the presence or absence of a mushroom-shaped titanium tip. Either a so-called ‘one’ piece catheter type with only a connection at the pump or a two-segment catheter are used.
Surgical implantation technique drug delivery system
Implantation is performed under local anaesthesia with intravenous sedation or general anaesthesia, With the patient in lateral decubitus position, a 3– to 4-cm dorsal midline incision is made at the planned implantation level up to the muscular fascia. On level L2-L3 or L1-L2 a silicone catheter is obliquely inserted into the intrathecal space, using a 15-G (8731SC catheter) or 16-G (Ascenda catheter) introduction (Tuohy) needle. The introduction needle is inserted 1–2 cm using a paramedian approach  to prevent catheter shearing and crushing by the frequent movements of the vertebral spinal process when a midline approach is applied. Under fluoroscopy the catheter is advanced to the mid-thoracic level [43,44,45]. Some physicians claim that positioning of the tip at the high thoracic, or even cervical position, gives a better result on the upper extremities; however, this has not yet been proved [46, 47]. At the abdominal site, a subcutaneous pocket is made in which the pump is placed and sutured using the outside suture loops of the pump. The pump catheter segment is connected suturelessly to the pump and tunnelled from the pump pocket to the dorsal incision, where it is connected to the spinal catheter part. The excess catheter length should be placed dorsal to the pump in the pocket.
Radiological examination after implantation of an intrathecal drug delivery system
Since the quality of the perioperative fluoroscopic images is insufficient for detailed information, routine postoperative plain radiography is performed after all of the surgical procedures and manipulations. For adequate interpretation, plain radiography of the pump and the entire implanted catheter in two directions is required .
Development of a stepwise interpretation schedule
A stepwise interpretation of the standard plain radiographic images has been developed (Appendix) to offer the radiologist a systematic approach for the evaluation of all parts of the intrathecal delivery system on plain radiography. This stepwise interpretation is based on expert opinion.
The normal and abnormal plain radiographic findings are described in a 14-step approach, a pump roller examination is also described.
Fourteen-step interpretation of standard plain radiographic images
Previous radiographs available?
Comparison with previous radiological examinations is required to detect subtle or overt changes in the location and position of the pump and catheter.
Type of catheter used.
The position of the pump is described by reporting the pump apex (Figs. 1a, 3, 4, 5, 6, 7, 9, 10, and 12) as a location on the clock face and the abdominal quadrant in which the pump is placed. To exclude pump rotations, it is important to compare the current pump position with previous radiological images. Rotations about the horizontal axis are known as the Reel syndrome [48, 49] (Figs. 4 and 6), resulting in traction on the catheter and risk of disconnection at the level of the pump-catheter (Fig. 5) or catheter-catheter connection (Fig. 6b).
Excess pump catheter segment behind the pump
In common practice, the excess catheter length is positioned behind the pump. In case the catheter surplus is located above the pump reservoir, refilling with medication or injecting contrast material in the catheter access port might result in catheter puncturing. Catheter perforation can result in dose adjustment problems, or even in a severe withdrawal syndrome .
With the magnification view the radiopaque identifier with the company logo and three alphabetic letters can be recognised opposite the pump apex (Fig. 7). When the pump is rotated around its longitudinal axis an odd number of times, the identifier is visible as a mirror image. This rotation was originally described in cardiac pacemakers  and is known as Twiddler’s syndrome. The rotation can occur either spontaneously or as result of repeated twiddling with the device by the patient. The syndrome has also been described in an implanted pump for intrathecal drug administration . After several rotations (Fig. 10), the catheter will occlude, rupture or dislodge resulting in termination of the drug delivery.
Catheter pump segment
The 8731SC thick-walled pump catheter segment is clearly visible (Figs. 1a, 2, 5 and 10) and in most cases the spinal segment is also visible (Figs. 2, 9, 10 and 11) The lack of opacity of the Ascenda catheter creates problems with visualisation of the pump segment (Figs. 5 and 6). Normally, this segment is clearly visible in older catheters.
The standard position of the clearly visible catheter-catheter connector is near the spine (Figs. 3, 4, 6b and 10). However, if the connection is placed in the pump pocket, recognition can be difficult. In the 8731SC catheter, the connector is visible as a two-pin connector (Fig. 10), in the Ascenda catheter as a needle (Figs 3 and 8a,b,e), and in older catheters often as a sharp small two-pin connector.
Spinal segment of the catheter outside the spinal canal
The spinal segment of the 8731SC catheter has a smaller diameter than the pump segment and seems to be vulnerable to twisting, migration (Fig. 9) and shearing (Fig. 10). The pump segment and the spinal segment of the Ascenda catheter have the same small diameter. The improved mechanical properties make it less vulnerable. Kinking cannot be demonstrated on plain radiography in all implanted catheters. For a definite conclusion, additional investigations, such as injection of contrast material or scintigraphy, are needed.
A folded anchor in the 8731SC catheter (Fig. 2) and an unfolded anchor in the Ascenda catheter (Fig. 3) are present. In older catheters, both folded and unfolded anchors can be found. At the anterior-posterior view, anchors are often poorly visible (Fig. 3a); whereas on the lateral image they are adequately visible (Fig. 3b).
Catheter insertion, midline or paramedian?
Inserting an intrathecal catheter using the midline approach raises the risk of catheter crushing due to spinal column movements (Fig. 10). Therefore, a paramedian approach is the standard implantation technique.
Spinal intrathecal catheter segment
Due to the poor visibility of the Ascenda catheter, the thoracic or the cervical vertebral column catheter segment is inadequately imaged. This leads to lack of information on the position of the catheter.
Due to the titanium end, the radiopaque tip can be recognised (Figs. 3 and 6). Attention must be paid to retained catheter fragments (Fig. 11). This can occur at the time of catheter insertion, removal or as a late complication [52, 53]. There is no consensus about the treatment of retained fragments. Both conservative [52, 53] (Fig. 11) and surgical treatment [52, 54] are performed. Nevertheless, serious complications like subarachnoid haemorrhage [39, 55, 56] and migration into the ventricle  are reported. Special attention must be paid if an intrathecal fragment also remains partially outside the spinal canal. Leakage of CSF with the development of postural headache, a pseudomeningocele  or even an intracranial hypotension syndrome could occur. However, sometimes no CSF leakage is present (Fig. 10). In a conservative approach, the position of the retained catheter fragment should be followed-up over time.
Radio-opaque catheter tip
In the latest catheters, a titanium tip has been built into the end of the catheter. In these intrathecal catheters, on plain radiography this tip is recognised as a ball at the end of the catheter (Figs. 2, 3 and 6).
Special pump roller examination
If the rotor of the pump stalls, a two-tone emergency alarm will sound. After interrogation with the device programmer, the device display indicates a ‘Motor Stall’. When no motor stall is indicated and this is not derived from the pump logs, a roller study should be performed in case failure is suspected (Fig. 12). In this procedure, the pump is programmed in the continuous infusion mode, using a preset, without activation and with a priming bolus of 10 μl with a duration of 1 min. With fluoroscopy, the rotor is visualised, thereby reducing the aperture. A plain radiographic image is made and the preset bolus delivery is activated. After 2 min, a new plain radiographic image is made and the two images are compared. In a normal pump function, the rollers have moved approximately 60° from their original position. The extra radiopaque dot on one of the roller arms helps to visualise the roller movement (Fig. 12).
Although intrathecal drug administration using an implanted pump system has been employed for many years in therapy-resistant spasticity and intractable pain, knowledge on diagnostic imaging during adverse events remains limited.
The main reasons for this limited knowledge include (1) the diminished frequency of catheter-related treatment failures due to advancements in manufacturing and (2) the limited application of the treatment in different clinics. While plain radiography is the mainstay for the diagnosis of drug delivery device-related adverse events, radiologists play an important role in early diagnosis. An awareness of typical radiographic images in relation to intrathecal catheter failure is important to avoid a (sometimes life-threatening) withdrawal syndrome. The most frequent causes of drug delivery failure are migration, damage, disconnection and occlusion of the spinal catheter. In our opinion, applying the presented 14-step analysis and increasing the awareness of abnormal radiological findings will help physicians to avoid a life-threatening withdrawal syndrome.
A limitation of this proposal is that our approach has not yet been validated but is based on our expert opinion. Due to the present lack of high-quality evidence, we strongly believe that, as a first step in quality improvement, the current variation in radiological practice should be avoided. The stepwise approach, as proposed by our group, might be an effective first step towards raising the quality of care related to troubleshooting for intrathecal drug delivery with implanted systems.
Penn RD, Savoy SM, Corcos D et al (1989) Intrathecal baclofen for severe spinal spasticity. N Engl J Med 320(23):1517–1521
Delhaas EM, Beersen N, Redekop WK, Klazinga NS (2008) Long-term outcomes of continuous intrathecal baclofen infusion for treatment of spasticity: a prospective multicenter follow-up study. Neuromodulation 11(3):227–236
van Hilten BJ, van de Beek WJ, Hoff JI, Voormolen JH, Delhaas EM (2000) Intrathecal baclofen for the treatment of dystonia in patients with reflex sympathetic dystrophy. N Engl J Med 343(9):625–630
Hassenbusch SJ, Stanton-Hicks M, Covington EC, Walsh JG, Guthrey DS (1995) Long-term intraspinal infusions of opioids in the treatment of neuropathic pain. J Pain Symptom Manag 10(7):527–543
Rauck RL, Cherry D, Boyer MF, Kosek P, Dunn J, Alo K (2003) Long-term intrathecal opioid therapy with a patient-activated, implanted delivery system for the treatment of refractory cancer pain. J Pain 4(8):441–447
Nance P, Meythaler J (1999) Intrathecal drug therapy. Phys Med Rehabil Clin North Am 10(2):385–401
Care MASMoHaL-T (2005) Intrathecal baclofen pump for spasticity: an evidence-based analysis. Ont Health Technol Assess Ser 5(7):1–93
Zahavi A, Geertzen JH, Middel B, Staal M, Rietman JS (2004) Long term effect (more than five years) of intrathecal baclofen on impairment, disability, and quality of life in patients with severe spasticity of spinal origin. J Neurol Neurosurg Psychiatry 75(11):1553–1557
Rekand T, Gronning M (2011) Treatment of spasticity related to multiple sclerosis with intrathecal baclofen: a long-term follow-up. J Rehabil Med 43(6):511–514
Miracle AC, Fox MA, Ayyangar RN, Vyas A, Mukherji SK, Quint DJ (2011) Imaging evaluation of intrathecal baclofen pump-catheter systems. AJNR Am J Neuroradiol 32(7):1158–1164
Stempien L, Tsai T (2000) Intrathecal baclofen pump use for spasticity: a clinical survey. Am J Phys Med Rehabil 79(6):536–541
Stetkarova I, Yablon SA, Kofler M, Stokic DS (2010) Procedure- and device-related complications of intrathecal baclofen administration for management of adult muscle hypertonia: a review. Neurorehabil Neural Repair 24(7):609–619
Awaad Y, Rizk T, Siddiqui I, Roosen N, McIntosh K, Waines GM (2012) Complications of intrathecal baclofen pump: prevention and cure. ISRN Neurol 2012:575168
Dardashti S, Chang EY, Kim RB, Alsharif KI, Hata JT, Perret DM (2013) False positive radiographical evidence of pump catheter migration into the spinal cord. Pain Physician 16(5):E627–E630
Borowski A, Littleton AG, Borkhuu B et al (2010) Complications of intrathecal baclofen pump therapy in pediatric patients. J Pediatr Orthop 30(1):76–81
Haranhalli N, Anand D, Wisoff JH et al (2011) Intrathecal baclofen therapy: complication avoidance and management. Childs Nerv Syst 27(3):421–427
Motta F, Antonello CE (2014) Analysis of complications in 430 consecutive pediatric patients treated with intrathecal baclofen therapy: 14-year experience. J Neurosurg-Pediatr 13(3):301–306
Stetkarova I, Brabec K, Vasko P, Menel L (2015) Intrathecal baclofen in spinal spasticity: frequency and severity of withdrawal syndrome. Pain Phys 18(4):E633–E641
Motta F, Antonello CE (2016) Comparison between an Ascenda and a silicone catheter in intrathecal baclofen therapy in pediatric patients: analysis of complications. J. Neurosurg. Pediatr.:1-6. doi: 10.3171/2016.4.peds15646
Cardoso AL, Quintaneiro C, Seabra H, Teixeira C (2014) Cardiac arrest due to baclofen withdrawal syndrome. BMJ Case Rep
Reeves RK, Stolp-Smith KA, Christopherson MW (1998) Hyperthermia, rhabdomyolysis, and disseminated intravascular coagulation associated with baclofen pump catheter failure. Arch Phys Med Rehabil 79(3):353–356
Alden TD, Lytle RA, Park TS, Noetzel MJ, Ojemann JG (2002) Intrathecal baclofen withdrawal: a case report and review of the literature. Childs Nerv Syst 18(9–10):522–525
Zuckerbraun NS, Ferson SS, Albright AL, Vogeley E (2004) Intrathecal baclofen withdrawal: emergent recognition and management. Pediatr Emerg Care 20(11):759–764
Dario A, Tomei G (2004) A benefit-risk assessment of baclofen in severe spinal spasticity. Drug Saf 27(11):799–818
Hansen CR, Gooch JL, Such-Neibar T (2007) Prolonged, severe intrathecal baclofen withdrawal syndrome: a case report. Arch Phys Med Rehabil 88(11):1468–1471
Douglas AF, Weiner HL, Schwartz DR (2005) Prolonged intrathecal baclofen withdrawal syndrome. J Neurosurg 102(6):1133–1136
Bellinger A, Siriwetchadarak R, Rosenquist R, Greenlee JDW (2009) Prevention of intrathecal baclofen withdrawal syndrome successful use of a temporary intrathecal catheter. Reg Anesth Pain Med 34(6):600–602
Smith TR, Mithal DS, Park A, Bohnen A, Adel J, Rosenow JM (2013) Emergent intrathecal baclofen withdrawal after pseudomeningocele aspiration. Pain Phys 16(2):E113–E118
Zheng K, Brodsky JB (2015) Spinal surgery and abrupt intrathecal baclofen withdrawal. A A Case Rep 5(9):160–161
Green LB, Nelson VS (1999) Death after acute withdrawal of intrathecal baclofen: case report and literature review. Arch Phys Med Rehabil 80(12):1600–1604
Meinck HM, Tronnier V, Rieke K, Wirtz CR, Flugel D, Schwab S (1994) Intrathecal baclofen treatment for stiff-man syndrome: pump failure may be fatal. Neurology 44(11):2209–2210
Sampathkumar P, Scanlon PD, Plevak DJ (1998) Baclofen withdrawal presenting as multiorgan system failure. Anesth Analg 87(3):562–563
Coffey RJ, Edgar TS, Francisco GE et al (2002) Abrupt withdrawal from intrathecal baclofen: recognition and management of a potentially life-threatening syndrome. Arch Phys Med Rehabil 83(6):735–741
Ross JC, Cook AM, Stewart GL, Fahy BG (2011) Acute intrathecal baclofen withdrawal: a brief review of treatment options. Neurocrit Care 14(1):103–108
Watve SV, Sivan M, Raza WA, Jamil FF (2012) Management of acute overdose or withdrawal state in intrathecal baclofen therapy. Spinal Cord 50(2):107–111
Francisco GE, Saulino MF, Yablon SA, Turner M (2009) Intrathecal baclofen therapy: an update. PM R 1(9):852–858
Fremondiere F, Saout V, Lacoeuille F et al (2014) Isotopic scintigraphy combined with computed tomography: a useful method for investigating inefficiency of intrathecal baclofen. J Rehabil Med 46(7):712–714
Dastgir A, Ranalli NJ, MacGregor TL, Aldana PR (2015) Baclofen pump catheter leakage after migration of the abdominal catheter in a pediatric patient with spasticity. J Neurosurg Pediatr 16(3):335–339
Hnenny L, Sabry HA, Raskin JS, Liu JJ, Roundy NE, Dogan A (2015) Migrating lumbar intrathecal catheter fragment associated with intracranial subarachnoid hemorrhage. J. Neurosurg. Spine 22(1):47–51
Delhaas E, Froberg A, Verzijlbergen F, van der Lugt A, Harhangi B, Huygen F (2016) Isotopic Scintigraphy coupled with computed tomography for the investigation of intrathecal baclofen device malfunction. Arch Phys Med Rehabil 97(9):1595
Fremondiere F, Lacoeuille F, Sher A et al (2016) Isotopic Scintigraphy coupled with computed tomography for the investigation of intrathecal baclofen device malfunction. Arch Phys Med Rehabil 97(4):646–649
Follett KA, Burchiel K, Deer T et al (2003) Prevention of intrathecal drug delivery catheter-related complications. Neuromodulation 6(1):32–41
Burns AS, Meythaler JM (2001) Intrathecal baclofen in tetraplegia of spinal origin: efficacy for upper extremity hypertonia. Spinal Cord 39(8):413–419
Ordia JI, Fischer E, Adamski E, Chagnon KG, Spatz EL (2002) Continuous intrathecal baclofen infusion by a programmable pump in 131 consecutive patients with severe spasticity of spinal origin. Neuromodulation 5(1):16–24
Sivakumar G, Yap Y, Tsegaye M, Vloeberghs M (2010) Intrathecal baclofen therapy for spasticity of cerebral origin—does the position of the intrathecal catheter matter? Childs Nerv Syst 26(8):1097–1102
Albright AL, Turner M, Pattisapu JV (2006) Best-practice surgical techniques for intrathecal baclofen therapy. J Neurosurg 104(4 Suppl):233–239
McCall TD, MacDonald JD (2006) Cervical catheter tip placement for intrathecal baclofen administration. Neurosurgery 59(3):634–640
Carnero-Varo A, Perez-Paredes M, Ruiz-Ros JA et al (1999) “Reel syndrome”: a new form of Twiddler’s syndrome? Circulation 100(8):e45–e46
Alvarez-Acosta L, Romero Garrido R, Farrais-Villalba M (2014) Hernandez Afonso J (2014) Reel syndrome: a rare cause of pacemaker malfunction. BMJ Case Rep. doi:10.1136/bcr-2014-204545
Bayliss CE, Beanlands DS, Baird RJ (1968) The pacemaker-twiddler’s syndrome: a new complication of implantable transvenous pacemakers. Can Med Assoc J 99(8):371–373
Moens M, De Smedt A, Brouns R (2011) Opioid withdrawal due to Twiddler syndrome. Neurology 77(1):86
Olivar H, Bramhall JS, Rozet I et al (2007) Subarachnoid lumbar drains: a case series of fractured catheters and a near miss. Can J Anaesth 54(10):829–834
Forsythe A, Gupta A, Cohen SP (2009) Retained intrathecal catheter fragment after spinal drain insertion. Reg Anesth Pain Med 34(4):375–378
Vodapally MS, Thimineur MA, Mastroianni PP (2008) Tension pseudomeningocele associated with retained intrathecal catheter: a case report with a review of literature. Pain Physician 11(3):355–362
Nakaji P, Consiglieri GD, Garrett MP, Bambakidis NC, Shetter AG (2009) Cranial migration of a baclofen pump catheter associated with subarachnoid hemorrhage: case report. Neurosurgery 65(6):E1212–E1213
Guppy KH, Silverthorn JW, Akins PT (2011) Subarachnoid hemorrhage due to retained lumbar drain. J Neurosurg Spine 15(6):641–644